The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A
Open accessAbstract
Objectives: To derive a model and examine the performance of first‐trimester combined screening by maternal age, fetal nuchal translucency (NT) thickness and maternal serum free beta‐human chorionic gonadotropin (β‐hCG) and pregnancy‐associated plasma protein‐A (PAPP‐A). Methods: Prospective combined screening for trisomy 21 was carried out at 11 + 0 to 13 + 6 weeks in 56 771 singleton pregnancies, including 56 376 cases with a normal karyotype or delivery of a phenotypically normal baby (unaffected group) and 395 cases with trisomy 21. The blood test and ultrasound scan were carried out in the same visit. In each case the maternal age‐related risk for trisomy 21 at term was calculated and adjusted according to the gestational age at the time of screening to derive the a‐priori risk. The measured NT was transformed into a likelihood ratio using the mixture model of NT distributions. The measured free β‐hCG and PAPP‐A were converted into a multiple of the median (MoM) for gestational age, adjusted for maternal weight, ethnicity, smoking status, method of conception and parity, and a likelihood ratio was subsequently calculated. The likelihood ratios for NT and for the biochemical markers were multiplied by the a‐priori risk to derive the patient‐specific risk. Detection rates and false‐positive rates were calculated by taking the proportions with risks above a given risk threshold after adjustment for maternal age according to the distribution of pregnancies in England and Wales in 2000–2002. These standardized rates were compared with detection and false‐positive rates estimated using Monte Carlo methods to sample from the modeled Gaussian distributions. Results: The performance of screening based on the model was in good agreement with that observed in our population. In a strategy for first‐trimester combined screening where the blood test and scan are carried out in the same visit it was estimated that, for false‐positive rates of 3% and 5%, the detection rates were 92% and 94%, respectively, at 11 weeks, 85% and 90% at 12 weeks, and 79% and 83% at 13 weeks. In an alternative strategy, with the blood taken at 10 weeks and the measurement of NT performed at 12 weeks, the estimated detection rates were 94% and 96% for false‐positive rates of 3% and 5%, respectively. Conclusions: The aim of the first‐trimester scan is not just to screen for trisomy 21 but also to diagnose an increasing number of fetal malformations. In this respect the ability to visualize fetal anatomy is better at 12–13 weeks than at 11 weeks. Consequently, the ideal gestation for combined testing in the same visit would be 12 weeks. An alternative strategy, with the blood taken at 10 weeks and the measurement of NT performed at 12 weeks, is associated with higher detection rates of trisomy 21. However, the cost of two‐stage screening would be higher and, in addition, the potential advantage in terms of detection rate may be eroded by the likely increased non‐compliance with the additional step. Copyright © 2008 ISUOG. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · Technometrics · doi:10.1198/tech.2005.s303 · Cited by 17,923
Draper, N. R., & Smith, H. (1998) · Wiley Series in Probability and Statistics · doi:10.1002/9781118625590 · Cited by 5,024
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
Snijders, R., Noble, P., Sebire, N., Souka, A., & Nicolaides, K. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11280-6 · Cited by 1,572
First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome
Malone, F. D., Canick, J. A., Ball, R. H., Nyberg, D. A., Comstock, C. H., Bukowski, R., Berkowitz, R. L., Gross, S. J., Dugoff, L., Craigo, S. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043693 · Cited by 1,081
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities
Nicolaides, K. H. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.03.090 · Cited by 626
Self-citationCUCKLE, H. S., WALD, N. J., & THOMPSON, S. G. (1987) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1987.tb03115.x · Cited by 604
Wald, N. J., Rodeck, C., Hackshaw, A. K., Walters, J., Chitty, L., & Mackinson, A. M. (2003) · Health Technology Assessment · doi:10.3310/hta7110 · Cited by 585
Spencer, K., Souter, V., Tul, N., Snijders, R., & Nicolaides, K. H. (1999) · Ultrasound in Obstetrics & Gynecology · doi:10.1046/j.1469-0705.1999.13040231.x · Cited by 568
Self-citationAbsence of nasal bone in fetuses with trisomy 21 at 11–14 weeks of gestation: an observational study
Cicero, S., Curcio, P., Papageorghiou, A., Sonek, J., & Nicolaides, K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06709-5 · Cited by 527
Self-citation
Cited by
Gil, M. M., Quezada, M. S., Revello, R., Akolekar, R., & Nicolaides, K. H. (2015) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.14791 · Cited by 807
Self-citationChiu, R. W. K., Akolekar, R., Zheng, Y. W. L., Leung, T. Y., Sun, H., Chan, K. C. A., Lun, F. M. F., Go, A. T. J. I., Lau, E. T., To, W. W. K., et al. (2011) · BMJ · doi:10.1136/bmj.c7401 · Cited by 774
Self-citationScreening for fetal aneuploidies at 11 to 13 weeks
Nicolaides, K. H. (2011) · Prenatal Diagnosis · doi:10.1002/pd.2637 · Cited by 642
Self-citationISUOG Practice Guidelines: performance of first‐trimester fetal ultrasound scan
(2013) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.12342 · Cited by 621
Self-citationChallenges in the diagnosis of fetal non‐chromosomal abnormalities at 11–13 weeks
Syngelaki, A., Chelemen, T., Dagklis, T., Allan, L., & Nicolaides, K. H. (2011) · Prenatal Diagnosis · doi:10.1002/pd.2642 · Cited by 498
Self-citationFirst-Trimester Prediction of Hypertensive Disorders in Pregnancy
Poon, L. C. Y., Kametas, N. A., Maiz, N., Akolekar, R., & Nicolaides, K. H. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.127977 · Cited by 466
Self-citationAkolekar, R., Syngelaki, A., Sarquis, R., Zvanca, M., & Nicolaides, K. H. (2011) · Prenatal Diagnosis · doi:10.1002/pd.2660 · Cited by 444
Self-citationTurning the Pyramid of Prenatal Care
Nicolaides, K. H. (2011) · Fetal Diagnosis and Therapy · doi:10.1159/000324320 · Cited by 357
Self-citationMaternal risk factors for hypertensive disorders in pregnancy: a multivariate approach
Poon, L. C. Y., Kametas, N. A., Chelemen, T., Leal, A., & Nicolaides, K. H. (2010) · Journal of Human Hypertension · doi:10.1038/jhh.2009.45 · Cited by 330
Self-citationISUOG Practice Guidelines (updated): performance of 11–14‐week ultrasound scan
International Society of Ultrasound in Obstetrics and Gynecology, Bilardo, C. M., Chaoui, R., Hyett, J. A., Kagan, K. O., Karim, J. N., Papageorghiou, A. T., Poon, L. C., Salomon, L. J., Syngelaki, A., et al. (2023) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.26106 · Cited by 275
Self-citationKagan, K. O., Wright, D., Valencia, C., Maiz, N., & Nicolaides, K. H. (2008) · Human Reproduction · doi:10.1093/humrep/den224 · Cited by 263
Self-citationPrediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks
Nanda, S., Savvidou, M., Syngelaki, A., Akolekar, R., & Nicolaides, K. H. (2011) · Prenatal Diagnosis · doi:10.1002/pd.2636 · Cited by 254
Self-citationPrediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks
Karagiannis, G., Akolekar, R., Sarquis, R., Wright, D., & Nicolaides, K. H. (2011) · Fetal Diagnosis and Therapy · doi:10.1159/000321694 · Cited by 195
Self-citationKagan, K. O., Valencia, C., Livanos, P., Wright, D., & Nicolaides, K. H. (2009) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.6264 · Cited by 175
Self-citationKagan, K. O., Cicero, S., Staboulidou, I., Wright, D., & Nicolaides, K. H. (2009) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.6318 · Cited by 172
Self-citationProspective validation of first-trimester combined screening for trisomy 21
Kagan, K. O., Etchegaray, A., Zhou, Y., Wright, D., & Nicolaides, K. H. (2009) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.6412 · Cited by 132
Self-citationPoon, L. C. Y., Karagiannis, G., Staboulidou, I., Shafiei, A., & Nicolaides, K. H. (2011) · Prenatal Diagnosis · doi:10.1002/pd.2520 · Cited by 115
Self-citationLooney, P., Stevenson, G. N., Nicolaides, K. H., Plasencia, W., Molloholli, M., Natsis, S., & Collins, S. L. (2018) · JCI Insight · doi:10.1172/jci.insight.120178 · Cited by 112
“These cases consisted of all the women presenting for their combined screening for aneuploidies at the Fetal Medicine Centre, London, United Kingdom, who gave their consent (19, 20).”
BackgroundSelf-citationPlacental Volume at 11–13 Weeks’ Gestation in the Prediction of Birth Weight Percentile
Plasencia, W., Akolekar, R., Dagklis, T., Veduta, A., & Nicolaides, K. H. (2011) · Fetal Diagnosis and Therapy · doi:10.1159/000324318 · Cited by 86
Self-citationWagner, P., Sonek, J., Hoopmann, M., Abele, H., & Kagan, K. O. (2016) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.15829 · Cited by 68
Self-citationZhang, L., Dong, D., Sun, Y., Hu, C., Sun, C., Wu, Q., & Tian, J. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.17854 · Cited by 42
Souka, A. P., Pilalis, A., Papastefanou, I., Salamalekis, G., & Kassanos, D. (2012) · Prenatal Diagnosis · doi:10.1002/pd.3976 · Cited by 21
Prodan, N. C., Wiechers, C., Geipel, A., Walter, A., Siegmann, H. J., Kozlowski, P., Hoopmann, M., & Kagan, K. O. (2022) · Fetal Diagnosis and Therapy · doi:10.1159/000523738 · Cited by 14
Self-citation
Metadata
- Authors
- Kagan, K. O., Wright, D., Baker, A., Sahota, D., & Nicolaides, K. H.
- Venue
- Ultrasound in Obstetrics & Gynecology
- Publisher
- Wiley
- Published
- 2008-05-06
- Volume
- 31
- Issue
- 6
- Pages
- 618-624
- ISSN
- 0960-7692 (ISSN-L)
- 1469-0705
- OpenAlex
- W2075791178
- Cited by
- 378
- References
- 30
- FWCI
- 40.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.